BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31353231)

  • 1. Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial.
    Khan TZ; Gorog DA; Arachchillage DJ; Ahnström J; Rhodes S; Donovan J; Banya W; Pottle A; Barbir M; Pennell DJ
    J Clin Lipidol; 2019; 13(5):788-796. PubMed ID: 31353231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial.
    Khan TZ; Pottle A; Pennell DJ; Barbir MS
    Atheroscler Suppl; 2015 May; 18():103-8. PubMed ID: 25936312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial.
    Khan TZ; Hsu LY; Arai AE; Rhodes S; Pottle A; Wage R; Banya W; Gatehouse PD; Giri S; Collins P; Pennell DJ; Barbir M
    Eur Heart J; 2017 May; 38(20):1561-1569. PubMed ID: 28453721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a).
    Khan TZ; Hartley A; Haskard D; Caga-Anan M; Pennell DJ; Collins P; Barbir M; Khamis R
    Antioxidants (Basel); 2021 Jan; 10(1):. PubMed ID: 33477712
    [No Abstract]   [Full Text] [Related]  

  • 5. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina.
    Khan TZ; Pottle A; Pennell DJ; Barbir MS
    Glob Cardiol Sci Pract; 2014; 2014(1):3-12. PubMed ID: 25054114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can Lipoprotein Apheresis Offer a Therapeutic Role in the Management of Patients With Refractory Angina and Raised Lipoprotein(a)?
    Khan TZ
    Ther Apher Dial; 2018 Feb; 22(1):5-7. PubMed ID: 29405622
    [No Abstract]   [Full Text] [Related]  

  • 7. Transient increase of plasma lipoprotein(a) in patients with unstable angina pectoris. Does lipoprotein(a) alter fibrinolysis?
    Oshima S; Uchida K; Yasu T; Uno K; Nonogi H; Haze K
    Arterioscler Thromb; 1991; 11(6):1772-7. PubMed ID: 1834167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein apheresis is effective in reducing lipoprotein(a) levels and in improving symptoms in a patient with refractory angina secondary to accelerated coronary artery disease.
    Ibrahim M; Ussen B; Pottle A; Barbir M
    J Clin Lipidol; 2012; 6(2):192-4. PubMed ID: 22385553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis.
    Alessi MC; Parra HJ; Joly P; Vu-Dac N; Bard JM; Fruchart JC; Juhan-Vague I
    Clin Chim Acta; 1990 Apr; 188(2):119-27. PubMed ID: 2143123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
    Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
    Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
    Ezhov MV; Afanasieva OI; Il'ina LN; Safarova MS; Adamova IY; Matchin YG; Konovalov GA; Akchurin RS; Pokrovsky SN
    Atheroscler Suppl; 2017 Nov; 30():187-192. PubMed ID: 29096836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris.
    Hoffmeister HM; Jur M; Wendel HP; Heller W; Seipel L
    Circulation; 1995 May; 91(10):2520-7. PubMed ID: 7743613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
    Ezhov MV; Safarova MS; Afanasieva OI; Pogorelova OA; Tripoten MI; Adamova IY; Konovalov GA; Balakhonova TV; Pokrovsky SN
    Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
    Pokrovsky SN; Afanasieva OI; Safarova MS; Balakhonova TV; Matchin YG; Adamova IYU; Konovalov GA; Ezhov MV
    Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Lp(a) lipoprotein inhibit the fibrinolytic system?
    Halvorsen S; Skjønsberg OH; Berg K; Ruyter R; Godal HC
    Thromb Res; 1992 Nov; 68(3):223-32. PubMed ID: 1471070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical hemocompatibility of double-filtration lipoprotein apheresis comparing polyethersulfone and ethylene-vinyl alcohol copolymer membranes.
    Krieter DH; Jeyaseelan J; Rüth M; Lemke HD; Wanner C; Drechsler C
    Artif Organs; 2021 Sep; 45(9):1104-1113. PubMed ID: 33617653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a) apheresis.
    Pokrovsky SN; Afanasieva OI; Ezhov MV
    Curr Opin Lipidol; 2016 Aug; 27(4):351-8. PubMed ID: 27213629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low order correlations of lipoprotein(a) with other blood lipids and with coagulation and fibrinolysis parameters in hypertensive and diabetic patients.
    Donders SH; Lustermans FA; van Wersch JW
    Blood Coagul Fibrinolysis; 1992 Jun; 3(3):249-56. PubMed ID: 1386533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome.
    Ames PR; Lupoli S; Alves J; Atsumi T; Edwards C; Iannaccone L; Khamashta MA; Hughes GR; Brancaccio V
    Br J Rheumatol; 1997 Oct; 36(10):1045-50. PubMed ID: 9374919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.